Trial Profile

A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Registrational; Therapeutic Use
Acronyms ENESTFreedom
Sponsors Novartis; Novartis Farma; Novartis Pharma A.G.; Novartis Pharmaceuticals

13 Mar 2025 Status changed from active, no longer recruiting to completed.
29 Sep 2024 This trial has been completed in Denmark, as per European Clinical Trials Database record.
30 May 2021 Planned End Date changed from 19 Feb 2025 to 20 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com